Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Blockade of Metallothioneins 1 and 2 Increases Skeletal Muscle Mass and Strength.

Summermatter S, Bouzan A, Pierrel E, Melly S, Stauffer D, Gutzwiller S, Nolin E, Dornelas C, Fryer C, Leighton-Davies J, Glass DJ, Fournier B.

Mol Cell Biol. 2017 Feb 15;37(5). pii: e00305-16. doi: 10.1128/MCB.00305-16. Print 2017 Mar 1.

2.

MiR-210 promotes sensory hair cell formation in the organ of corti.

Riccardi S, Bergling S, Sigoillot F, Beibel M, Werner A, Leighton-Davies J, Knehr J, Bouwmeester T, Parker CN, Roma G, Kinzel B.

BMC Genomics. 2016 Apr 27;17:309. doi: 10.1186/s12864-016-2620-7.

3.

Identification of the C3a receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells.

Hannedouche S, Beck V, Leighton-Davies J, Beibel M, Roma G, Oakeley EJ, Lannoy V, Bernard J, Hamon J, Barbieri S, Preuss I, Lasbennes MC, Sailer AW, Suply T, Seuwen K, Parker CN, Bassilana F.

J Biol Chem. 2013 Sep 20;288(38):27434-43. doi: 10.1074/jbc.M113.497214. Epub 2013 Aug 12.

4.

The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium.

Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, Trifilieff A, Charlton SJ.

J Pharmacol Exp Ther. 2012 Nov;343(2):520-8. doi: 10.1124/jpet.112.194456. Epub 2012 Aug 1.

5.

R-Spondin potentiates Wnt/β-catenin signaling through orphan receptors LGR4 and LGR5.

Ruffner H, Sprunger J, Charlat O, Leighton-Davies J, Grosshans B, Salathe A, Zietzling S, Beck V, Therier M, Isken A, Xie Y, Zhang Y, Hao H, Shi X, Liu D, Song Q, Clay I, Hintzen G, Tchorz J, Bouchez LC, Michaud G, Finan P, Myer VE, Bouwmeester T, Porter J, Hild M, Bassilana F, Parker CN, Cong F.

PLoS One. 2012;7(7):e40976. doi: 10.1371/journal.pone.0040976. Epub 2012 Jul 16.

6.

Design and synthesis of a library of chemokine antagonists.

Bhalay G, Albrecht B, Akhlaq M, Baettig U, Beer D, Brown Z, Charlton S, Dunstan A, Bradley M, Gedeck P, Glen A, Howe T, Keller T, Leighton-Davies J, Li A, McCarthy C, Mocquet C, Owen C, Nicklin P, Rosethorne E.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6249-52. doi: 10.1016/j.bmcl.2011.09.013. Epub 2011 Sep 10.

PMID:
21940167
7.

Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication.

Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, Leighton-Davies J, Wilson CJ, Myer V, Cornellataracido I, Baryza J, Tallarico J, Joberty G, Bantscheff M, Schirle M, Bouwmeester T, Mathy JE, Lin K, Compton T, Labow M, Wiedmann B, Gaither LA.

J Virol. 2009 Oct;83(19):10058-74. doi: 10.1128/JVI.02418-08. Epub 2009 Jul 15.

8.

Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist.

Sayers I, Hawley J, Stewart CE, Billington CK, Henry A, Leighton-Davies JR, Charlton SJ, Hall IP.

Br J Pharmacol. 2009 Sep;158(1):277-86. doi: 10.1111/j.1476-5381.2009.00224.x. Epub 2009 Apr 30.

9.

Miniaturized receptor binding assays: complications arising from ligand depletion.

Carter CM, Leighton-Davies JR, Charlton SJ.

J Biomol Screen. 2007 Mar;12(2):255-66. Epub 2007 Jan 26.

PMID:
17259589
10.

In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.

Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D, Fozard JR, Leighton-Davies JR, Lewis CA, McEvoy L, Turner RJ, Trifilieff A.

J Pharmacol Exp Ther. 2006 May;317(2):762-70. Epub 2006 Jan 24.

11.

ATP priming of macrophage-derived chemokine responses in CHO cells expressing the CCR4 receptor.

Rosethorne EM, Leighton-Davies JR, Beer D, Charlton SJ.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):64-70. Epub 2004 May 27.

PMID:
15167983

Supplemental Content

Loading ...
Support Center